One America News Network OAN Staff Blake Wolf
The Food and Drug Administration (FDA) approved Moderna’s next generation lower-dose COVID-19 vaccines.
The new vaccine, called mNEXSPIKE was approved on Saturday for adults aged 65 and older, along with people aged 12 to 64 with at least one medical condition placing them at higher risk of COVID-19.
The newly approved vaccine is not a replacement for Moderna’s current COVID vaccine, but rather an additional choice for patients seeking a lower-dose option, as it contains one-fifth of Moderna’s other COVID vaccine, Spikevax.
“The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,” stated Moderna CEO Stéphane Bancel.
Read Full Article Here…(oann.com)
Home | Caravan to Midnight (zutalk.com)
Live Stream + Chat (zutalk.com)
